
HumanFirst, now part of ICON plc, offers the Atlas platform, a comprehensive SaaS solution for identifying and evaluating fit-for-purpose remote monitoring technologies including digital biomarkers and digital health technologies (DHTs) across clinical research, clinical care, and public health. The platform supports clinical trials by providing validated evidence and insights to accelerate patient-centered drug development. HumanFirst operates under ICON's legal and security frameworks, ensuring compliance with standards such as NIST CSF, SSAE SOC 2, and GDPR. The company serves pharmaceutical and clinical research organizations, leveraging AI and cloud technologies to deliver secure, scalable, and reliable digital health data solutions. HumanFirst's business model is subscription-based SaaS, with a focus on enterprise customers in the pharmaceutical and clinical research sectors. The company emphasizes data security, privacy, and regulatory compliance, and collaborates with research institutions like Mapi Research Trust to enhance its offerings.

HumanFirst, now part of ICON plc, offers the Atlas platform, a comprehensive SaaS solution for identifying and evaluating fit-for-purpose remote monitoring technologies including digital biomarkers and digital health technologies (DHTs) across clinical research, clinical care, and public health. The platform supports clinical trials by providing validated evidence and insights to accelerate patient-centered drug development. HumanFirst operates under ICON's legal and security frameworks, ensuring compliance with standards such as NIST CSF, SSAE SOC 2, and GDPR. The company serves pharmaceutical and clinical research organizations, leveraging AI and cloud technologies to deliver secure, scalable, and reliable digital health data solutions. HumanFirst's business model is subscription-based SaaS, with a focus on enterprise customers in the pharmaceutical and clinical research sectors. The company emphasizes data security, privacy, and regulatory compliance, and collaborates with research institutions like Mapi Research Trust to enhance its offerings.
Status: Acquired by ICON (announced Feb 29, 2024)
Product: Atlas platform — SaaS for evaluating and deploying digital biomarkers, eCOA, and digital health technologies
Customers: Enterprise pharmaceutical and clinical research organizations
Business model: Subscription-based SaaS
Total funding (reported): USD 14,900,000
Digital biomarkers, remote monitoring, eCOA deployment, and precision digital measures for clinical research and care.
2017
Digital health / Clinical research technology
Most recent disclosed round on May 31, 2021